Evidence map›Paper›PMID 33561334›Full record

ReviewThe Korean journal of internal medicine2021

2020 Korean guidelines for the management of metastatic prostate cancer.

In-Ho Kim, Sang Joon Shin, Byung Woog Kang, Jihoon Kang, Dalyong Kim, Miso Kim, Jin Young Kim, Chan Kyu Kim, Hee-Jun Kim, Chi Hoon Maeng and 17 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Korean journal of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Gender bias in shared decision-making among cancer care guidelines: A systematic review.Health expectations : an international journal of public participation in health care and health policy · 2023
    Pooled it
  2. Guideline
  3. Pooled it
  4. A pharmacoinformatic approach for studyingFrontiers in oncology · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

In-Ho KimDivision of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sang Joon ShinDivision of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Byung Woog KangDepartment of Oncology/ Hematology, Kyungpook National University Hospital, Daegu, Korea.
Jihoon KangDivision of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Dalyong KimDivision of Hematology & Medical Oncology, Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.
Miso KimDivision of Hematology-Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Jin Young KimDivision of Hemato-Oncology, Keimyung University Dongsan Hospital, Daegu, Korea.
Chan Kyu KimDivision of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Hee-Jun KimDivision of Hematology/Oncology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Chi Hoon MaengDivision of Medical Oncology-Hematology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea.
Kwonoh ParkMedical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.
Inkeun ParkDivision of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Woo Kyun BaeDepartment of Hemato-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Byeong Seok SohnDepartment of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea.
Min-Young LeeDivision of Hematology & Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
Jae Lyun LeeDepartment of Oncology and Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Junglim LeeDivision of Medical Oncology, Department of Internal Medicine, Daegu Fatima Hospital, Daegu, Korea.
Seung Taek LimDepartment of Oncology, Yonsei University Wonju College of Medicine, Wonju, Korea.
Joo Han LimDepartment of Hematology/Oncology, Inha University School of Medicine, Incheon, Korea.
Hyun ChangDivision of Medical Oncology, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea.
Joo Young JungDivision of Hemato-Oncology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.
Yoon Ji ChoiDivision of Hematology-Oncology, Department of Medicine, Korea University Anam Hospital, Seoul, Korea.
Young Seok KimDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jaeho ChoDepartment of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Jae Young JoungCenter for Urologic Cancer, National Cancer Center, Goyang, Korea.
Se Hoon ParkDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Hyo Jin LeeDepartment of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.

Funding

Ministry of Health and Welfare 1720150
6 · The paper itself

Abstract

In 2017, Korean Society of Medical Oncology (KSMO) published the Korean management guideline of metastatic prostate cancer. This paper is the 2nd edition of the Korean management guideline of metastatic prostate cancer. We updated recent many changes of management in metastatic prostate cancer in this 2nd edition guideline. The present guideline consists of the three categories: management of metastatic hormone sensitive prostate cancer; management of metastatic castration resistant prostate cancer; and clinical consideration for treating patients with metastatic prostate cancer. In category 1 and 2, levels of evidence (LEs) have been mentioned according to the general principles of evidence-based medicine. And grades of recommendation (GR) was taken into account the quality of evidence, the balance between desirable and undesirable effects, the values and preferences, and the use of resources and GR were divided into strong recommendations (SR) and weak recommendations (WR). A total of 16 key questions are selected. And we proposed recommendations and described key evidence for each recommendation. The treatment landscape of metastatic prostate cancer is changing very rapid and many trials are ongoing. To verify the results of the future trials is necessary and should be applied to the treatment for metastatic prostate cancer patients in the clinical practice. Especially, many prostate cancer patients are old age, have multiple underlying medical comorbidities, clinicians should be aware of the significance of medical management as well as clinical efficacy of systemic treatment.

Indexed as

Prostatic NeoplasmsHumansMaleRepublic of KoreaPractice guidelineProstate neoplasms

Identifiers

PMID33561334
PMCPMC8137395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.